Suchergebnisse - "Sarilumab"

PubPharm (319)

91

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19 : An Open Label Randomized Clinical Trial

enthalten in: Frontiers in medicine | 2022

von García-Vicuña, R. | Rodriguez-García, S. | Abad-Santos, F. | +10

92

Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany

enthalten in: Rheumatology advances in practice | 2022

von Tony, H. | Feist, E. | Aries, P. | +7

93

Immune-related adverse events of biological immunotherapies used in COVID-19

enthalten in: Frontiers in pharmacology | 2022

von Baracaldo-Santamaría, D. | Barros-Arias, G. | Hernández-Guerrero, F. | +2

94

Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling

in: Frontiers in Immunology | 2022

von Gaetano Zizzo | Antonio Tamburello | Laura Castelnovo | +5

95

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

in: Медицинский совет | 2022

von N. V. Muravyeva | B. S. Belov

96

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab

in: Arthritis Research & Therapy | 2022

von Andrea Rubbert-Roth | Daniel E. Furst | Stefano Fiore | +5

97

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis

in: Emerging Microbes and Infections | 2022

von Su-Yeon Yu | Dae-Hyup Koh | Miyoung Choi | +4

98

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations

in: Infectious Disease Reports | 2022

von Andrea Marino | Antonio Munafò | Egle Augello | +7

99

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial

in: Frontiers in Medicine | 2022

von Rosario García-Vicuña | Rosario García-Vicuña | Sebastián C. Rodriguez-García | +13

100

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts

in: Pharmaceutics | 2022

von Annett Klinder | Janine Waletzko-Hellwig | Marie-Luise Sellin | +5